source
- ADARx Pharmaceuticals, backed by AbbVie, files for IPO with three RNAi drugs in clinical trialsADARx Pharmaceuticals, an RNA interference biotech based in San Diego, disclosed its plan to go public in a Friday night SEC filing. The company aims to capitalize on the current momentum in biotec…
- AbbVie’s etentamig shows strong survival and response gains in Phase 3 multiple myeloma trialAbbVie reported that its investigational bispecific T‑cell engager, etentamig, significantly reduced the risk of disease progression or death in a Phase 3 study of patients with relapsed or refract…